Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...
The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...
@2024 - All Right Reserved.
Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...
Greater radiotracer uptake on PSMA-PET is associated with an increased likelihood of achieving a PSA decline in response to lutetium-177. The finding is from a study of 97 patients with mCRPC treated ...
Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer ...
Image of PSA screening. Latest findings are from a post hoc analysis of the phase 3 VISION trial. Greater prostate-specific anitgen (PSA) decline from baseline in men with metastatic ...
News Medical on MSN
UCLA Health launches novel clinical trial for recurrent prostate cancer
The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals when used alongside stereotactic body radiotherapy (SBRT), a focused form of ...
WEST LAFAYETTE, Ind., June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced ...
In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...
Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In this video, Tanya Dorff, MD, head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback